UK: Can "Reach-through" Claims be Enforced? The US Federal Court Decision in University Of Rochester v G. D. Searle & Co., Inc et al.

Last Updated: 11 July 2003
Article by Paul Cole
Non-steroidal aspirin-like drugs act by inhibiting prostaglandin synthesis, but suffer from side effects, in particular gastrointestinal bleeding which has been responsible for some 16,000 deaths annually in the US consequent on their long-term use. It is now known that aspirin inhibits the action of two closely related enzymes, one of which called COX-1 is responsible for gastrointestinal protection and the other of which called COX-2 releases substances responsible for pain and inflammation.

There is room for controversy about who should be acknowledged as the discoverer of COX-2 and its structure and physiological role. Professor Philip Neederman in St Louis, USA has been credited with having first hypothesized that there are two COX enzymes. Professor Daniel Simmons of Brigham Young University, Utah claims to have discovered COX-2 in 1989 and published his team’s findings in April 19911. However, Dr Donald A. Young at the University of Rochester (the team involved in the present dispute) claimed to have built on the work of the Simmons team and to have described in successive US patent applications dating back to 22nd September 1992:

  • That there are two COX (PGHS) genes, one of which was constitutively expressed and is called COX-1 and the other of which is responsive to regulatory control and is called COX-2.
  • That COX-2 is a unique isoform of cyclooxygenase which in contrast to COX-1 is dramatically up-regulated by growth factors, tissue injury and proinflammatory cytokines, and plays a major role in peripheral inflammation.
  • The cDNA and predicted amino acid sequence of COX-2.

Based on these discoveries the Rochester team produced cell lines stably expressing COX-2, which could be used to provide a simple in vitro screen for new drugs that would inhibit inflammation and which were predicted to be free from side effects.

Compounds that acted as COX-2 inhibitors were in existence as of September 1992 although they had, according to the University, not been specifically disclosed for human use2. For example, EP-A-0317332 (Taisho Pharma) described and claimed sulfonanilide compounds that showed anti-inflammatory, antipyretic and analgesic effects combined with a decrease in gastrointestinal side effects. Amongst these was a compound NS-398 which has been widely used in experimental work e.g. in the rat, but which has not been developed for clinical use. The activity of this compound was acknowledged by the Rochester team in their US patent 6048850 (the patent in issue) which states: "The fact that induced cyclooxygenase activity is blocked by NS-398, a specific inhibitor of PGHS-2, confirms that induction of PGHS-2 is responsible for increased prostaglandin production in cytokine-treated astrocytes".

The Rochester inventors did not consider that what they had invented was merely a research tool, and they wished to "reach-through" to claim the clinically useful compounds that resulted from their discoveries. The main claim of their patent read:

"A method for selectively inhibiting PGHS-2 [COX-2] activity in a human host, comprising administering a non-steroidal compound that selectively inhibits activity of the PGHS-2 gene in a human host in need of such treatment."

The patent was granted on 11th April 2000, and legal proceedings against Searle and Pfizer were started on that day. On the following day the University announced in a press release that they had been awarded a pioneering patent for the use of the entire class of COX-2 inhibitors that included the blockbuster drugs Celebrex and Vioxx, and that over the 17-year life of the patent the royalty payments could yield the University billions of dollars, making it the most lucrative pharmaceutical patent in history.

The hopes of the University received a potentially fatal setback following an application by the defendants for summary judgment on the grounds of lack of written description and non-enablement because the patent disclosed no selective COX-2 inhibitor and finding such compounds required further empirical research.

In its opinion3 the US District Court accepted the defendant’s arguments. It explained that although the University may have laid the groundwork for the later invention of COX-2 inhibitors, they had not taken the last critical step of isolating such a compound or developing a process by which a skilled person would be directly lead to such a compound, and that even if the inventors were reasonably certain that the necessary compound existed and could eventually be found, there was no showing in the patent that they knew this to be a fact. The Court summarised its conclusions as regards written description4 in the following passage:

"In effect, then, the ‘850 patent claims a method that cannot be practiced until one discovers a compound that was not in the possession of, or known to, the inventors themselves. Putting the claimed method into practice awaited someone actually discovering a necessary component of the invention. In some ways, this is reminiscent of the search for the so-called "philosopher’s stone," eagerly sought after by medieval alchemists, which supposedly would transmute lead into gold. While the Court does not mean to suggest that the inventors’ significant work in this field is on a par with alchemy, the fact remains that without the compound called for in the patent, the inventors could no more be said to have possessed the complete invention claimed by the ‘850 patent than the alchemists possessed a method of turning base metals into gold."

The court’s interest, if not fascination, with the history of the philosopher’s stone is further demonstrated by the following footnoted passage:

"A patent for the philosopher’s stone was actually issued during the reign of Edward III. "The invention we now regard as a superstition, but the application was referred by the King to a commission, which reported favorably upon it, and the patent issued apparently upon what we now regard as sound doctrine, that the invention was new and useful." McKeever v. United States, 14 Ct.Cl. 396 (1878). It is not apparent whether the patentee claimed actually to possess the stone, or whether he simply described it in terms of its function, in the hope that he would be entitled to royalties should it ever be discovered."

The Court further held that the patent was non-enabling because it provided little guidance about selecting a particular compound or narrowing the range of candidates, with the result that a suitable compound could not be found without undue experimentation. Although the need for trial and error experimentation was not per se decisive, there had to be reasonable detail to enable members of the public to understand and carry out the invention and tossing out the mere germ of an idea was not enough5. Searle had started a screening program in August 1992, and by May 1993 had screened some 600 compounds and identified a number of selective COX-2 inhibitors, but the Court held that this merely demonstrated that considerable research was necessary to turn the claimed invention into reality. Although not cited in the judgment, a significant paper by Kunin et al6 foreshadowed the conclusion reached by the Court and expresses a firm view at a senior level within the USPTO that reach-through claims should not be allowed.

What might be said in support of the University on appeal? A major weakness in their position is that the reference in claim 1 to "a human host" is essential to distinguish their method from previous proposals such as the NS-398 compound. Even if an appellate Court could be persuaded that the task of finding some compounds that are active in the sense that they selectively inhibit COX-2 was within routine skill once COX-2 had been isolated and its structure and physiological role had become known, it might reasonably refuse to say that the further task of identifying the subclass of active compounds that were safe to administer to humans was also routine. On the other hand, the discovery of COX-2 was a scientific breakthrough, not alchemy. The prediction that useful inhibitors would follow quickly upon the discovery of the enzyme proved true. It could reasonably be argued that subsequent events demonstrate the incorrectness of the Court’s view concerning non-enablement. The commercially successful compounds Celebrex and Vioxx appeared in the late 1990’s, which, in the timescale of the pharmaceutical industry, was rapid and it is therefore disingenuous to say that the necessary skills were lacking There is the further argument that the written description requirement should not be applied so strictly that the reward for discovering COX-2 inhibitors goes in its entirety to the discoverers of the active compounds and is not shared with the academic scientists whose breakthrough enabled those compounds to be discovered. Such arguments are unlikely to appeal to the CAFC in the existing state of US case law, but if the case were taken up by the Supreme Court7 might a less onerous view of what patent law should demand of researchers in academic institutions give rise to a different result?

Footnotes

1 Xie et al., Proc. Nat’l. Acad. Sci. USA, 1991, 2692-2696 (April 1991), see also the deposited sequence at AAA58433.

2 The early development of COX-2 inhibitors is extensively discussed in the UK case Monsanto v Merck [2000] RPC 77 (HC), [2000] RPC 709 (CA) which concerns inter alia non-enablement of a patent claiming a Markush group of compounds, some of whose members had been experimentally demonstrated not to be selective COX-2 inhibitors as alleged in the specification.

3 Unites States District Court, Western District of New York, 00-CV-616L, Larimer J. 5th March 2003, downloadable from http://www.nywd.uscourts.gov/decision/20030305_00cv6161_larimer.pdf.

4 For the written description requirement in biotechnology patents see: Regents of the University of California v. Eli Lilly & Co., 119 F.3d 1559, 1568 (Fed. Cir. 1997), cert. denied, 523 U.S. 1089 (1998); Fiers, 984 F.2d at 1171; Enzo Biochem, Inc. v. Gen-Probe Inc., 285 F.3d 1013 (Fed. Cir. 2002), rehearing 296 F.3d 1316. Cases found non-persuasive because the patent specification contained enough information to lead a skilled person to the claimed compound included: Union Oil Co. v. Atlantic Richfield Co., 208 F.3d 989 (Fed. Cir. 2000), cert. denied, 531 U.S. 1183 (2001); In re Herscher, 591 F.2d 693 (C.C.P.A. 1979), and In re Edwards, 568 F.2d 1349 (C.C.P.A. 1978).

5 See, inter alia: W.L. Gore & Associates, Inc. v. Garlock, Inc., 721 F.2d 1540, 1557 (Fed. Cir. 1983); Genentech, Inc. v. Novo Nordisk A/S, 108 F.3d 1361, 1365 (Fed. Cir.), cert. denied, 522 U.S. 963 (1997); In re Wands, 858 F.2d 731, 736-40 (Fed. Cir. 1988); Enzo Biochem, Inc. v. Calgene, Inc. ("Calgene"), 188 F.3d 1362, 1371 (Fed. Cir. 1999); Amgen, Inc. v. Chugai Pharm. Co., Ltd., 927 F.2d 1200, 1213 (Fed. Cir.).

6 Stephen G. Kunin, Deputy Commissioner for Patent Examination Policy at the USPTO, Mark Nagumo, Administrative Patent Judge in the Board of Patent Appeals and Interferences, Brian Stanton, Technology Center 1600 Practice Specialist , Linda S. Therkorn, Patent Examination Policy Advisor, Office of the Deputy Commissioner for Patent Examination Policy, Stephen Walsh, Associate Solicitor, Office of General Counsel at the USPTO, American University Law Review, 51, 609-638, 2002. The article can be downloaded from
http://www.wcl.american.edu/journal/lawrev/51/Kunin.pdf.

7 Review of CAFC decisions by the Supreme Court is rare. However, there may be an argument that the Court should review this case because the question whether and in what circumstances reach-through claims are allowable affects the balance of risks and rewards as between academic and industrial research over an important range of technologies.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances. 

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.